Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leflunomide and malononitriloamides.

H T Silva1, R E Morris

  • 1Nephrology Division, Escola Paulista de Medicina, São Paulo, Brazil.

Expert Opinion on Investigational Drugs
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling MOF-808 photocycle and its interaction with luminescent guests.

Physical chemistry chemical physics : PCCP·2024
Same author

Genotype by environment interaction for Holstein cattle populations using autoregressive and within- and across-country multi-trait reaction norms test-day models.

Animal : an international journal of animal bioscience·2021
Same author

Genetic evaluation for latent variables derived from factor analysis in broilers.

British poultry science·2019
Same author

A note on transgenerational epigenetics affecting egg quality traits in meat-type quail.

British poultry science·2018
Same author

Transgenerational epigenetic variance for body weight in meat quails.

Journal of animal breeding and genetics = Zeitschrift fur Tierzuchtung und Zuchtungsbiologie·2018
Same author

Nature of the Spin Liquid Ground State in a Breathing Kagome Compound Studied by NMR and Series Expansion.

Physical review letters·2017

Leflunomide, an immunomodulatory drug, shows efficacy in rheumatoid arthritis and transplantation models. Its active metabolite, A77 1726, inhibits immune cell proliferation, with ongoing trials exploring optimal dosing and novel analogues.

Area of Science:

  • Immunology
  • Pharmacology
  • Rheumatology

Background:

  • Leflunomide is an immunomodulatory drug with demonstrated efficacy in autoimmune disease models and transplantation.
  • Its primary active metabolite, A77 1726 (a malononitriloamide), is responsible for its therapeutic effects.
  • The precise mechanisms of action for malononitriloamides are still under investigation.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of leflunomide in patients with advanced rheumatoid arthritis.
  • To investigate the in vitro and in vivo mechanisms of action of leflunomide and its metabolite A77 1726.
  • To explore the potential of malononitriloamide analogues for immunosuppression in transplantation.

Main Methods:

  • Phase II clinical trials assessed leflunomide efficacy and tolerability in rheumatoid arthritis patients.

Related Experiment Videos

  • In vitro and in vivo studies examined the effects of A77 1726 and analogues on immune cell function.
  • Preclinical models of transplantation are evaluating the immunosuppressive potential of novel analogues.

    • Main Results:

    • Leflunomide demonstrated high tolerability and efficacy in Phase II trials for rheumatoid arthritis.
    • A77 1726 inhibits T- and B-cell proliferation, immunoglobulin production, and cell adhesion.
    • Potential mechanisms include inhibition of de novo pyrimidine biosynthesis and tyrosine kinase activity.
    • Higher doses (25 mg) showed improved efficacy but increased adverse effects.

    Conclusions:

    • Leflunomide is an effective treatment for active rheumatoid arthritis.
    • A77 1726's immunomodulatory effects are linked to pyrimidine biosynthesis and tyrosine kinase inhibition.
    • Further research, including Phase III trials and analogue development, is warranted for rheumatoid arthritis and transplantation.